Cellectar Biosciences’ CLR 131 has achieved an overall survival of greater than 22 months in advanced multiple myeloma patients, the company announced today.

“We continue to make meaningful progress on our CLR 131 program and are encouraged by the observed clinical outcomes to date,” Cellectar Biosciences President and CEO Jim Caruso said in a statement. “We look forward to reporting data from the fourth cohort of our Phase 1 trial as well as the single and multi-dose Phase 2 study when available.”

According to a release, Phase 1 of the clinical trial is fully enrolled and Phase 2 remains actively enrolling.

The trial is still ongoing, with potential overall survival to increase over time.